New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 3, 2013
18:08 EDTCRISCuris announces $30M at-the-market equity offering
Curis disclosed in a regulatory filing that it entered into a sales agreement with Cowen to sell up to $30M of the company’s common stock through an at-the-market equity offering.
News For CRIS From The Last 14 Days
Check below for free stories on CRIS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 8, 2014
07:22 EDTCRISBiotech Industry Organization to hold a conference
Subscribe for More Information
April 7, 2014
16:14 EDTCRISCuris reports CUDC-907, CUDC-427 data
Subscribe for More Information
16:11 EDTCRISCuris, Debiopharm Group report preclinical data for Debio 0932
Curis and Debiopharm Group announced the presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research, or AACR, that demonstrated synergy between Debio 0932 and various standard of care, or SOC, agents in multiple in vitro and xenograft models of non-small cell lung cancer, or NSCLC, and renal cell carcinoma, or RCC. Debio 0932 is currently being investigated in a Phase 1/2 trial in combination with SOC agents in patients with advanced NSCLC and in a Phase 1 trial in combination with everolimus, a mTOR inhibitor, in advanced RCC patients. In a high throughput combination screen performed with six different human NSCLC cell lines, Debio 0932 demonstrated consistent synergy with microtubule and mTOR/ Akt targeting agents across all six cell lines. Additionally, Debio 0932 also showed strong synergy with everolimus in multiple patient derived and conventional RCC cell lines. Similar synergy and anti-tumor activity with Debio 0932 in combination with these agents was also demonstrated in human xenograft models of NSCLC and RCC.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use